LMB 100

Drug Profile

LMB 100

Alternative Names: LMB100

Latest Information Update: 10 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer National Cancer Institute (USA); Roche
  • Class Antineoplastics; Immunotoxins; Proteins
  • Mechanism of Action Megakaryocyte potentiating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • Phase I Mesothelioma
  • Preclinical Solid tumours

Most Recent Events

  • 25 Apr 2018 Selecta Biosciences has patent protection for LMB 100 for Mesothelioma/Pancreatic Cancer
  • 21 Feb 2018 Phase-I clinical trials in Mesothelioma (Combination therapy, Second-line therapy or greater, Late-stage disease, In adults, In the elderly) in USA (IV) (NCT03436732)
  • 02 May 2017 LMB 100 licensed to Selecta Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top